The global digital therapeutics market, valued at USD 6.77 billion in 2023, is projected to reach USD 43.88 billion by 2032, with a CAGR of 23.2%. Digital therapeutics (DTx) encompasses software and devices facilitating evidence-based therapeutic interventions for disease prevention and management. These tools address various disorders, including mental health, diabetes, respiratory, and cardiovascular diseases. Rising chronic disease prevalence, such as cancer and heart failure, drives market demand. Pharmaceutical industries and physicians increasingly adopt DTx solutions, spurring market growth. Research and development efforts by market players drive innovation. For example, Akili, Inc. received FDA clearance for its ADHD treatment video game. The COVID-19 pandemic has further accelerated market growth, with increased demand for remote diagnosis and treatment. Major players’ initiatives to manage patients during the pandemic also contribute to product adoption.

Know More